PROM1 and cancer: However, several studies [14, 15] revealed no significant statistical significance between age and pathological response after NCRT, and even Leow’s [16] study indicated that young age was a predictor of a lower pCR rate after NCRT because young patients may have more aggressive pathological features, associated with higher CD133 + cancer stem cell burden, thereby resulting in a poorer response to neoadjuvant therapy.